BCG vaccine could restore proper immune response in type 1 diabetes
A new FDA-approved clinical trial done by the researchers at the Massachusetts General Hospital, United States shows restoration of immune response to produce insulin in mice models with advanced type 1 diabetes (T1D) with the genetic vaccine bacillus Calmette-Guerin (BCG). Researchers made this vaccine by using a harmless strain of bacteria which causes tuberculosis, which was approved earlier by United States FDA for the treatment of bladder cancer.
Type 1 diabetes (T1D) occurs due to the attack of T cells (Tregs) on the immune system. Researchers say genetic bacillus Calmette-Guerin (BCG) vaccine can restore permanent gene expression and restore T cells (Tregs). Researchers have completed successful type 1 diabetes (T1D) reversal trials of mice models. Subsequent human trials of BCG vaccine were successful and the study results were expected by the end of 2017.
Now the researchers are enrolling type 1 diabetes (T1D) patients for a five-year Phase II trial of BCG vaccine involving 150 adult individuals. They wanted to see the improvement or reversal of type 1 diabetes (T1D) with a repeated BCG vaccination. The principal investigator of the study was Dr. Denise Faustman, PhD, Director, Immunology Laboratory, the Massachusetts General Hospital, Boston, United States. The study findings were presented at the 75th Scientific Sessions of the American Diabetes Association.
Excess weight may reduce early death risk for older adults with diabetes
A study by the researchers at the Capital Medical University, Beijing, China shows risk reduction to an early death by 18 percent and extend lifespan during later life with excess weight (obese or overweight or higher BMI) in older adults with diabetes. Earlier studies show adverse health risks with obesity or overweight. But this study results show benefits to older adults with diabetes during later life by holding some excess weight. Researchers came to this conclusion after analyzing 250,000 type 1 diabetes (T1D) or type 2 diabetes (T2D) patients from 20 studies.
In their studies, researchers assessed body mass index (BMI) of the participants and investigated the association of BMI with all-cause mortality risk. Researchers have done follow-up studies between 2.9 and 16.7 years. Their study results show a lower risk of all-cause mortality with body mass index (BMI) in the range of overweight or obese compared with individuals with normal body mass index (BMI).
Researchers unable to explain the link between longer lifespan for older adults patients with diabetes and overweight (or obesity or higher BMI) in later life. Earlier studies show an inverse association between insulin resistance and muscle mass. Body weight reduces as lean muscle mass reduces with age. Body weight loss in older adults could lead to worse health outcomes. Co-author of the study was Yu Jie Zhou, from An Zhen Hospital, the Capital Medical University, Beijing, China. The study findings were published in the Journal of Diabetes Investigation, under the title "Impact of obesity on mortality in patients with diabetes: Meta-analysis of 20 studies including 250,016 patients".
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.